Secondary Adjuvant Long Term Study With Arimidex

Exclusion Criteria

• •1. Premenopausal patients or patients with non definable menopausal statusat time of randomisation
• •2. Apparent secondary malignant tumor or status after secondary malignant tumor (Exceptions: simultaniously appearing bilateral breast carcinoma, estrogen- and or progesteronereceptor positive on both sides at the time of diagnosis; in situ carcinomaof the cervix and basal cell carcinoma of the skin)
• •3. General contraindication respectively hypersensitivity to Anastrozol.
• •4. In-situ carcinoma of any size with or without Mb. Paget of the Mamilla respectively T4 tumor at the time of first diagnosis.
• •5. Receptor unknown or negative at time of diagnosis respectively at beginning of primary endocrine therapy
• •6. Known liver- and/or kidneyinsufficiency
• •7. Performance Index \>2 according to WHO
• •8. Regular intake of hormon supplement as well as Hormone Replacement Therapy (HRT) more than 6 months since primary surgery of the mamma carcinoma
• •9. Serious accessory disease, that prevents the adjuvant therapy according to protocol and/or the regular follow-up care.
• •10. Lacking compliance of the patient
• •11. Legal incompetence and/or other circumstances, that prevent the patient from understanding the nature, meaning and consequences of the clinical trial
• •12. Existing psychiatrical diseaseaccording to ICD (especially alcohol addiction) et the time of admission into the study